A/Prof Blombery is Head of the Molecular Haematology Laboratory at the Peter MacCallum Cancer Centre (PMCC) and the lead of the Wilson Centre for Blood Cancer Genomics.
He also hold positions as Clinical Haematologist (PMCC), Clinical Lead of Bioinformatics (Pathology - PMCC), Clinical Lead of Genetic Haematology tumour substream (PMCC), Senior Clinical Fellow (University of Melbourne) and Clinical Research Fellow, Transfusion Research Unit (Monash University).
As lead of the Molecular Haematology Laboratory/Wilson Centre, A/Prof Blombery leads the largest clinical molecular haematology laboratory in Australia focused on delivering personalised genomic testing for patients with blood cancer. In this role he supervises a team of over 30 people including pathologists, medical scientists, research scientists, haematology fellows/registrars, bioinformaticians, software engineers and technicians.
A/Prof Blombery also leads a large research program in translational genomics across all aspects of blood cancer including bone marrow failure, lymphoid genomics, measurable residual disease and resistance mechanisms to targeted therapy.
Through this research program A/Prof Blombery has made key discoveries including the first resistance mutation described for the targeted agent, venetoclax, as well as describing multiple new blood cancer entities including a novel subtype of acute lymphoblastic leukaemia.
His laboratory acts as central laboratory for multiple investigator initiated studies including the novel INTERCEPT study (Prof Andrew Wei) – a platform study investigating the role of MRD in decision making in acute myeloid leukaemia as well as performing correlative work for multiple ALLG trials (COALITION, LEVERAGE, TREBL-2, PACIFIC).
